Sudden cardiac death, presumed arrhythmic in origin, occurs in over 350,000 subjects annually in the United States alone. It continues to be a major national health care concern despite important advances that have been made in the surgical and electrode catheter ablative techniques as well as implantable devices in the control of life-threatening ventricular tachyarrhythmias responsible for such deaths. Because such nonpharmacologic approaches are not always applicable to very large numbers of patients and, because of the size of the problem, drug therapy is likely to remain a very significant modality for the reduction of arrhythmia mortality in susceptible patients. The presence of arrhythmias, symptomatic as well as asymptomatic, in a patient with cardiac disease is a sensitive marker of risk for arrhythmic death. It has been confirmed by a number of systematic studies in relatively large numbers of patients with a varying spectrum of cardiac disease; this relationship is no longer in doubt. What has not been clear, however, is whether suppression of such arrhythmias might lead to a significant reduction in arrhythmic mortality. Much recent and evolving data bears an important and practical relevance on this issue.
Sudden arrhythmic deaths for the most part occur in a highly unpredictable manner almost as if they result from transient electrophysiologic derangements, sometimes spontaneously reversible and at other times leading to arrhythmic deaths. Because of their entirely unpredictable nature, the occurrences of the arrhythmias responsible for sudden death might be considered simply as electrical accidents. As far as drug therapy for life-threatening ventricular arrhythmias are concerned, several questions may be asked. Does one aim to prevent the arrhythmias occurring by fundamentally altering the vulnerable substrate so there is less electrical instability or by merely producing cosmetically acceptable palliation of the manifestation of risk? Can acute responses of antiarrhythmic drugs in terms of suppression of naturally occurring ventricular arrhythmias or those induced by provocative maneuvers such as programmed electrical stimulation of the heart be predictive of fatal and nonfatal arrhythmic events longterm? These questions are of clinical relevance since they pertain to the subject of "guided" antiarrhythmic drug therapy of ventricular tachycardia and fibrillation. The title of this editorial is taken from an extremely thoughtful and focused review of the evolution of the management of malignant ventricular tachyarrhythmias by So0 G. Kim (1). The data summarized therein merits continuing scrutiny and emphasis until the results of the ongoing trials on drugs and devices are known. It is likely they will bring a measure of uniformity of thought and practice to the rational choice in approach from among the various available therapeutic modalities for mortality reduction in patients at risk of arrhythmic death. By its very nature, death from ventricular fibrillation is unpredictable because even though the patient in whom it is likely to occur often is identifiable, it is in a statistical sense rather than on an individual basis. This is demonstrated well in the case of out-of-hospital cardiac arrest. How does one design therapy for what is clearly an electrical accident? The physician, having the responsibility for selecting the type of preventive therapy that might be appropriate for such a patient resuscitated from cardiac arrest, needs to have confidence that the treatment given acutely will indeed have the potential to prevent recurrences longterm. Against such a background, the concept of guided therapy of ventricular tachycardia and fibrillation (VTNF) was developed in the 1980s. It was promptly accepted by the cardiologic community, especially in North America. The principle was sim-ple. A defined degree of antiarrhythmic drug suppression of premature ventricular contractions or nonsustained ventricular tachycardia documented on Holter recoraings in patients ("responders") who presented with aborted cardiac arrest or sustained symptomatic monomorphic VT was highly predictive of mortality or arrhythmia recurrence. In contrast, patients in whom the arrhythmias were not controlled ("nonresponders") on the same or similar drug regimens did poorly (2). The alternative competing strategy also involved arrhythmia suppression (VTNF) but only that induced by programmed electrical stimulation (PES) (3). Here again, responses to acutely administered drug regimens in terms of prevention (responders) of inducible arrhythmia or lack of it (nonresponders) appeared to be highly predictive of long-term recurrences of the arrhythmia. It should be emphasized that in both instances, the initial test drugs were sodium-channel blockers administered either individually or in combination. The results of the subsequent studies, albeit essentially uncontrolled, appeared so compelling from the standpoint of the differences between the effects in responders versus nonresponders, that empiric therapy was rapidly superseded by therapy guided by Holter monitoring (HM) and especially PES. Indeed, the latter came to be regarded as the gold standard for judging drug therapy for VTNF, since it seemed to have a greater scientific validity (4).
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although neither technique has been validated against independent and inherently valid controls. As pointed out by Kim (l), no study has addressed the issue of whether better outcomes in responders treated with a drug are the direct result of drug effect itself. It is possible the acute testing process merely identifies patients with an inherently better prognosis. Furthermore, drug therapy in the case of V T N F is frequently discordant (l), and an antiarrhythmic drug in the same patient may be found effective by one technique but not by the other. One should also examine the intrinsic limitations of the two techniques in terms of the variability of response relative to the changes in the patient's adrenergic state, electrolyte milieu, and the progression of the clinical condition of the patient as a function of time (4). Thus, one may logically ask under what circumstances suppression by a drug regimen of an arrhythmia, spontaneous or induced, might be expected to reduce the likelihood of arrhythmic death. As is well known, the results of the Cardiac Arrhythmic Suppression Trials (CAST I & 11) showed a remarkable dichotomy between suppression or elimination of premature ventricular contractions and mortality (ie, increases in mortality) despite marked sup-pression of premature ventricular contractions (5,6). If the impact on mortality and arrhythmia suppression in the case of class I agents were completely dissociated in the case of one subset of patients at high risk of sudden death (eg, post-infarct survivors), surely it is inherently improbable that such a relationship might be substantially different in another subset of patients (eg, those with VTNF) if Holter-guided therapy were used. The proarrhythmic reactions of class I drugs is in fact greater in patients with manifest V T N F than in the survivors of acute infarction because of their greater derangement of left ventricular ejection fraction. It will be correspondingly more difficult to show benefit in mortality even if there was one. Thus, with-' out an appropriate control treatment limb that reflects the natural history of the patient having presented with V T N F at least once, it is impossible to ascertain whether a particular antiarrhythmic agent might exert an effect on mortality that is neutral, deleterious, or beneficial (4).
The issue has been further clouded by the outcome of the Electrophysiologic Versus Electrocardiographic Monitoring (ESVEM) trial (7,8) in which the predictive accuracy of HM and PES were compared in a randomized controlled study in patients with V T N F in whom both techniques were applicable. Six class I agents and sotalol were used as test agents. There were several major findings. First, there was no significant difference between the two techniques in predicting the long-term outcome in terms of arrhythmia recurrence, sudden death, or total cardiovascular mortality. Second, comparisons of sotalol (the prototype class 111 agent with beta-blocking property) versus six class I agents, collectively or individually, with respect to arrhythmia recurrence, sudden death, and cardiovascular or total mortality, provided a significant difference in favor of sotalol. The first of the two findings has been severely, but perhaps unjustifiably, criticized, while the second has been widely accepted. The notion that PES was a superior technique, more highly predictive, and more scientific has been deeply ingrained over a decade and a half but, as indicated above, never did it have a basis in controlled data. The controversy centers around factors such as the number of extrastimuli (eg, 2 versus 3) that were used for the induction of VT after drug therapy, the superiority of the technique over HM-but only in certain subsets of patients (eg, ischemic versus nonischemic substrates), and in the fact that the patients who actually qualified to enter the trial were from such a small percentage of the total number screened and that there were relatively few patients with aborted sudden cardiac death.
Guided AntiarrhythmicTherapy 0 Singh 9 I These criticisms, of course, stem from comparisons to previous data, all of which had been obtained from retrospective studies that carried the same limitations as ESVEM. Such studies had the added shortcoming of not being controlled. ESVEM was a controlled clinical trial in which the baseline characteristics of the study population were carefully balanced, and any referral bias that may be present would be randomly assigned to each treatment group. As pointed out by Kim (I), the subsequent analysis of the ESVEM data with respect to stimulation and suppression protocols revealed that the failure to detect the expected difference between PES and HM for guiding V T N F treatment did not stem from flaws in the protocol design.
As pointed out elsewhere (4,9) there are sound theoretical reasons why a genuine difference between PES and HM as predictive techniques for guiding drug therapy of VTNF might not exist.
Therefore, what is there in the findings of the ESVEM trial that a practical-minded clinician can draw from to meaningfully design prophylactic drug therapy for VTNF? On the surface, two conclusions can be reached. Since sotalol in ESVEM was superior to all six class I agents, individually and collectively class I agents should now be superseded by sotalol and other agents such as amiodarone (see below) and possibly beta-blockers (lo), which do not appear to increase mortality in patients with VTNF. It would also appear equally compelling that since PES and HM are equivalent techniques, drug therapy can be selected by serial drug testing either by HM or PES, depending on personal preference. Does this approach, however, necessarily ensure that the suppressant drug chosen on the strength of such a guided approach to therapy will in fact prolong survival? Does sotalol prolong survival by reducing the likelihood of sudden arrhythmic death? Can we prove it? ESVEM did not address this issue since the study did not include a placebo-controlled (or equivalent) arm. However, ESVEM was carried out before the era of widespread use of implantable defibrillator-cardioverters (IDCs), which can now be used as a background for placebo-controlled drug studies. The arrhythmia recurrence rate of 21% for sotalol compared to 44% for class I agents (P < .0007) at 1 year in ESVEM is consistent with the notion that the effects of drugs on the suppression of inducible or spontaneous V T N F are poorly predictive of the longterm outcome of drug treatment on the basis of acute responses using guided therapy. A similar difference was found in the case of other indices (eg. total mortality and cardiac mortality), but the possibility cannot be excluded that the effect of sotalol under these circumstances might be neutral or even deleterious as was evident in CAST (5,6).
Furthermore, the fact that sotalol was not as effective as class I drugs (such as mexiletine) in suppressing nonsustained VT on HM, although it reduced mortality to a greater extent than did class I agents, emphasizes the dichotomy between arrhythmia suppression and total mortality. The parallelism to the CAST data cannot be ignored. It is noteworthy that in ESVEM mexiletine was a more powerful suppressant of nonsustained VT than sotalol, but the latter had a clearly superior effect on total mortality. The fact that the techniques in ESVEM did not differ in predicting the outcome of drug therapy based on acute responses-although the two classes of drugs did differ in this regard and in their fundamental electrophysiologic characteristics-emphasizes that drug, rather than technique-specific responses, might be the crucial determinant of the outcomes of pharmacologic therapy of V T N F (4). In ESVEM, sotatol was superior to class I agents not because its effects could be predicted better with HM or PES. It is more likely that its electrophysiologic and pharmacodynamic effects "matched" better with the vulnerable substrate in contrast to the possibility of a "mismatch" in the case of class I agents as clearly exemplified in CAST (4).
Thus, it is becoming increasingly clear that to be able to demonstrate a favorable impact of a drug on arrhythmia mortality, controlled trials will need to focus on protocols in which the effects of drugs will need to be compared to those of placebo in subsets of patients at high risk. For example, as indicated above, patients with manifest V T N F protected by an ICD in both treatment limbs may need to be randomized to active drug and placebo to determine whether a drug is superior to placebo. Data from such studies are becoming available. Kuhlkamp et al. (1 1) performed drug testing with sotalol in 82 patients with V T N F and inducible arrhythmia. In 37, sotalol prevented inducibility (responders), and these patients were discharged on the drug at an appropriate dose. The remaining patients (nonresponders) had ICDs implanted (n = 45), and these patients were further randomized to no drug therapy (n = 22) or empiric sotalol (n = 23). All patients were followed for an approximately equivalent period of time. The VT recurrence rate on guided sotalol therapy was in 6 patients (16%), on ICD plus sotalol in 5 patients (22%), and 12 patients (55%) on ICD alone. Total mortality on guided sotalol was 5% (2 patients), 4% on sotalol plus ICD (1 patient), and 4% (1 patient) on ICD alone. Thus, the data indicates that clinical efficacy of sotalol is underestimated by PES response and the incidence of VT recurrence is independent of the results of PES drug testing. Kehoe et al. (12) have also presented data from 161 patients with V T N F in which the clinical outcomes were determined over a period of 2 years in responders (n = 86) and nonresponders (n = 75) to sotalol during testing by PES. No significant difference in the clinical outcomes between the two groups was demonstrated. These are compelling data and cast serious doubt about the intrinsic validity of guided therapy for patients with V T N F even in the case of sotalol. They make a strong case for the use of empiric therapy with the drug in controlling life-threatening ventricular arrhythmias.
Against such a background, it is timely to critically revisit the issue of empiric therapy with amiodarone in patients with VTNF. Amiodarone is a complex compound that has a low efficacy for preventing inducibility of V T N F by PES but that is an exceedingly potent agent for suppressing premature ventricular contractions and nonsustained VT (13) . Over a decade or more, it has been widely accepted that when cases of V T N F are not controlled well with class I agents using guided therapy, empiric amiodarone chronically administered is likely to control 60-80% of such patients (14) . In this context, the data from the randomized controlled study in cardiac arrest survivors-Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation Study (CAS-CADE)-are of great importance (15). In this study, patients (n = 228) resuscitated from out-of-hospital cardiac arrest not associated with myocardial infarction were randomized into two treatment limbs: 1. conventional therapy involving class I drugs selected on the basis of guided therapy (HM or PES), and 2. empiric amiodarone therapy with standardized dosage regimens followed for 6 years. Towards the end of the study, 46% of the patients (evenly distributed between the two treatment limbs) were given implantable ICDs. During the follow-up examinations, 23% of the patients treated with class I agents were declared failures at 1 year and 44% at 3 years, compared to 9% at 1 year and 2 4 8 at 3 years on empiric amiodarone (P < .007). At the end of 3 years, the cumulative rate of syncopal shocks from ICDs was 22% in the treatment limb with class I agents compared to 6% in patients on amiodarone (15) . The conclusion that has been drawn here is that empiric amiodarone therapy is clearly superior to guided therapy with class I agents, which no longer appear to have a role in the treatment of cardiac arrest survivors to prevent further recurrence. As in the case of sotalol in ESVEM, however, it is likely, but not completely certain, that amiodarone does prolong survival in absolute terms since no control treatment limb akin to placebo was used in CASCADE.
The question that has been repeatedly asked over the years is whether amiodarone therapy for V T N F can be improved further by guiding it with either PES or HM. Opinion on this issue remains somewhat divided among electrophysiologists. On the one hand, there has been substantive agreement that empiric amiodarone can be used ethically both for control of V T N F for clinical purposes and for the conduct of controlled clinical trials as is the case with ICD trials-CASH, AVID, and CIDs-in all of which the amiodarone treatment limb has been empiric (16, 17) . In none of these trials so far has a clear trend in favor of the ICD led to their premature termination. This suggests that if a difference exists between the device and the best drug therapy, the difference is small and favor could be in either direction. On the other hand, numerous electrophysiologists continue to advocate a role of PES-guided therapy in the case of amiodarone. It has been suggested that patients in whom the arrhythmia remains inducible on amiodarone therapy are at higher risk for VT recurrence with a greater total mortality, especially if the arrhythmia is hemodynamically unstable (1 8).
For these reasons, the article by Nasir et al. (19) in the current issue of the Joiirilal is of much importance. Theirs is one of the largest studies to address the issue of the predictive accuracy of serial electrophysiologic studies in the therapy of sustained ventricular arrhythmias treated with arniodarone. They evaluated 121 patients with sustained VT (mean left ventricular ejection fraction of about 32% and 85% with history of coronary artery disease) with programmed electrical stimulation before and after 2 and 6 weeks of amiodarone therapy. After 2 weeks of drug treatment only 14% of patients became noninducible; during follow-up study, VT recurrences (35% vs 2 4 8 ) and sudden death (12% vs 13.5%) were similar for responders versus nonresponders. These data after 2 weeks of therapy with amiodarone are the most relevant to clinical practice and here predictive accuracy is low. At 6 weeks, 11 of the 76 patients who were subjected to electrophysiologic evaluation were noninducible; they had a lower recurrence of arrhythmia, but the sudden death rate was not significantly different in responders and nonresponders. It was also of interest that 32 partial responders versus 31 nonresponders during long-term follow-up visits had similar arrhythmia recurrence and similar rates of sudden death. The authors' overall data indicate that nonin-ducibility of VT after 2 or 6 weeks of amiodarone therapy does not identify patients at low risk for sudden death and presumably total mortality. It should be stressed, however, that the data presented-by Nasir et al. is far from being flawless and numerous limitations may be cited. If it were the only study of its kind. it would not have a momentous impact. On the other hand, placed in the overall context of the sum total of data on guided therapy and the spectrum of data on amiodarone from previous reports, the data of Nasir et al. support the notion that it is extremely unlikely that therapy with amiodarone guided by PES is likely to constitute an improvement beyond the empiric approach. The data from the Congestive Heart Failure STAT (Survival Trial on Antiarrhythmic Therapy) trial in which the effects of amiodarone on total mortality was determined in a placebo-controlled protocol are of particular interest (20) . It was found that despite an extremely high degree of suppression of premature ventricular contractions and elimination of nonsustained VT on Holter recordings, no differences in sudden death or total mortality was noted in the case of responders and nonresponders in terms of suppression.
Therefore, although all but discounted in the recent past, data are becoming increasingly compelling that suggest the most successful drug therapies for morlality reduction in controlled clinical trials are those in which treatment has not been "guided" and has been essentially empirical. This is particularly striking in therapy with amiodarone and beta-blockers; the data on sotalol discussed in this editorial indicating that responders and nonresponders to PES-guided treatment had an identical clinical outcome also provide a rational basis for empiric therapy with sotalol. The advent of the ICDs now permits placebo-controlled trials with established as well as newer drugs in the evaluation of their efficacy in terms of total mortality, which is clearly the most relevant endpoint of such trials (15,16,20) .
The central issue of drug therapy for V T N F is clearly the drug specificity of response (4). Arrhythmias documented by HM or by PES can be viewed within this framework as representing two ends of a spectrum of severity of ventricular arrhythmias and those from simple and single premature ventricular contractions to V T N F occurring spontaneously or induced by PES constituting a continuum. Qualitatively, they may reflect gradations of substrate derangements relative to the levels of ventricular dysfunction and the seventy of underlying disease. The lethal potential of spontaneous or inducible' arrhythmias will also depend on the presence or absence of the intrinsic (ie, substrate-related) or extrinsic (eg, extracardiac) . modulating factors. Such modulating factors as ischemia, catecholamine discharge, changes in conduction, or temporal and spatial dispersion of myocardial refractoriness can be viewed simply as manifestations of the electrical instability of the substrate; however, none necessarily provide an approach to quantify the effect of therapy that might have an impact on mortality by graded changes in such manifestations. They appear to be only markers of risk. Such a risk is not likely to be altered without a fundamental improvement in the substrate, but it may be augmented by proarrhythmic reactions of drugs. Such a framework is supported by increasing data.
In the short term, responders and nonresponders selected on the basis of HM or PES and different classes of antiarrhythmic compounds may only indicate prognostic groups in the absence of treatment. The long-term influence on mortality is probably drug-specific in responders as well as in nonresponders rather than to technique-specific responses linked to a defined degree of suppression of spontaneous or inducible ventricular arrhythmias. Suppression of arrhythmias may need to be considered for relief of symptoms but, as clearly indicated by CAST (5,6) , not as surrogate for change in mortality. These considerations have important practical implications both for the manncr in which currently available drug regimens are selected for controlling life-threatening ventricular arrhythmias at the present and for how newer antiarrhythmic drugs are evaluated for introduction into clinical therapeutics for better V T N F control in the future.
